Pentoxifylline Add-On Therapy for Mild-to-Moderate Plaque Psoriasis

This study will evaluate whether pentoxifylline, when used as an add-on treatment to standard topical therapy, is effective and safe for adults with mild-to-moderate plaque psoriasis. Participants will be randomly assigned to receive either pentoxifylline or placebo twice daily for 12 weeks, while continuing their standard topical treatment. The study will compare improvement in psoriasis severity, itch, physician assessment, quality of life, and adverse events between the two groups. Participants will be followed for a total of 16 weeks.

Inclusion Criteria: * Adults aged 18 to 65 years. * Clinical diagnosis of mild-to-moderate plaque psoriasis, defined as Psoriasis Area and Severity Index (PASI) score 3 to 10 or body surface area (BSA) involvement 3% to 10%, as assessed by a physician. * Receiving stable standard topical therapy for at least 2 weeks before enrollment. * Able and willing to provide written informed consent. * Willing to comply with the study protocol and scheduled follow-up visits. Exclusion Criteria: * Use of biologic agents within 12 weeks before enrollment. * Psoriatic arthritis requiring systemic therapy. * Pregnant or breastfeeding. * Severe liver disease or severe kidney disease. * History of significant bleeding disorder or current use of anticoagulant therapy that cannot be appropriately managed. * Known hypersensitivity to pentoxifylline or related xanthine derivatives. * Any serious medical condition or safety concern that, in the investigator's judgment, makes participation inappropriate. * Refusal or inability to provide informed consent